Surgical Science Sweden Valuation

Q: What is the Fair Price of SUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SUS (SEK125.1) is trading below our estimate of [[fair value]] (SEK298.8)

Is SUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SUS (SEK125.1) is trading below our estimate of fair value (SEK298.8)

Significantly Below Fair Value: SUS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SUS?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for SUS. This is calculated by dividing SUS's market cap by their current preferred multiple.
What is SUS's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	SEK 6.38b

SUS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.8x
Enterprise Value/EBITDA	30.3x
PEG Ratio	1.1x

Price to Earnings Ratio vs Peers

How does SUS's PE Ratio compare to its peers?

The above table shows the PE ratio for SUS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	49.2x
ELOS B Elos Medtech	104.3x	n/a	SEK 5.7b
CEVI CellaVision	42.3x	24.0%	SEK 6.0b
ADDV A ADDvise Group	27.7x	18.3%	SEK 1.5b
ARJO B Arjo	22.4x	20.9%	SEK 11.2b
SUS Surgical Science Sweden	30.7x	27.0%	SEK 6.4b

Price-To-Earnings vs Peers: SUS is good value based on its Price-To-Earnings Ratio (30.7x) compared to the peer average (49.2x).

Price to Earnings Ratio vs Industry

How does SUS's PE Ratio compare vs other companies in the European Medical Equipment Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	25.1%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: SUS is expensive based on its Price-To-Earnings Ratio (30.7x) compared to the European Medical Equipment industry average (30.3x).

Price to Earnings Ratio vs Fair Ratio

What is SUS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SUS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	30.7x
Fair PE Ratio	27.6x

Price-To-Earnings vs Fair Ratio: SUS is expensive based on its Price-To-Earnings Ratio (30.7x) compared to the estimated Fair Price-To-Earnings Ratio (27.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SUS forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	SEK 125.10	SEK 204.00 +63.1%	19.1%	SEK 260.00	SEK 140.00	n/a	6
Jun ’25	SEK 144.60	SEK 208.17 +44.0%	15.7%	SEK 260.00	SEK 165.00	n/a	6
May ’25	SEK 157.10	SEK 221.50 +41.0%	13.6%	SEK 260.00	SEK 165.00	n/a	6
Apr ’25	SEK 151.70	SEK 222.33 +46.6%	13.7%	SEK 260.00	SEK 165.00	n/a	6
Mar ’25	SEK 155.20	SEK 228.17 +47.0%	9.1%	SEK 260.00	SEK 200.00	n/a	6
Feb ’25	SEK 179.30	SEK 239.00 +33.3%	11.1%	SEK 275.00	SEK 200.00	n/a	6
Jan ’25	SEK 182.50	SEK 236.50 +29.6%	13.8%	SEK 275.00	SEK 180.00	n/a	6
Dec ’24	SEK 175.50	SEK 236.50 +34.8%	13.8%	SEK 275.00	SEK 180.00	n/a	6
Nov ’24	SEK 129.00	SEK 242.33 +87.9%	12.0%	SEK 280.00	SEK 195.00	n/a	6
Oct ’24	SEK 150.30	SEK 254.00 +69.0%	14.4%	SEK 300.00	SEK 195.00	n/a	5
Sep ’24	SEK 164.20	SEK 263.00 +60.2%	9.3%	SEK 300.00	SEK 235.00	n/a	5
Aug ’24	SEK 237.00	SEK 272.20 +14.9%	10.9%	SEK 300.00	SEK 233.00	n/a	5
Jul ’24	SEK 241.20	SEK 272.20 +12.9%	10.9%	SEK 300.00	SEK 233.00	n/a	5
Jun ’24	SEK 230.00	SEK 272.20 +18.3%	10.9%	SEK 300.00	SEK 233.00	SEK 144.60	5
May ’24	SEK 187.10	SEK 233.40 +24.7%	18.6%	SEK 290.00	SEK 182.00	SEK 157.10	5
Apr ’24	SEK 169.20	SEK 232.40 +37.4%	18.9%	SEK 290.00	SEK 182.00	SEK 151.70	5
Mar ’24	SEK 172.10	SEK 236.00 +37.1%	21.4%	SEK 290.00	SEK 170.00	SEK 155.20	4
Feb ’24	SEK 148.70	SEK 239.00 +60.7%	23.1%	SEK 305.00	SEK 170.00	SEK 179.30	4
Jan ’24	SEK 164.70	SEK 239.00 +45.1%	23.1%	SEK 305.00	SEK 170.00	SEK 182.50	4
Dec ’23	SEK 148.40	SEK 262.00 +76.5%	16.9%	SEK 305.00	SEK 201.00	SEK 175.50	3
Nov ’23	SEK 160.80	SEK 273.00 +69.8%	17.2%	SEK 320.00	SEK 209.00	SEK 129.00	3
Oct ’23	SEK 150.50	SEK 273.00 +81.4%	17.2%	SEK 320.00	SEK 209.00	SEK 150.30	3
Sep ’23	SEK 156.30	SEK 273.00 +74.7%	17.2%	SEK 320.00	SEK 209.00	SEK 164.20	3
Aug ’23	SEK 149.40	SEK 272.00 +82.1%	18.6%	SEK 315.00	SEK 201.00	SEK 237.00	3
Jul ’23	SEK 152.30	SEK 272.00 +78.6%	18.6%	SEK 315.00	SEK 201.00	SEK 241.20	3
Jun ’23	SEK 154.10	SEK 307.50 +99.5%	2.4%	SEK 315.00	SEK 300.00	SEK 230.00	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.